Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Incobotulinumtoxin A
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Study Design of LONG RUN: A LONGitudinal evaluation and real-world evidence of uniquely purified incobotulinumtoxinA in treatment naïve participants, demonstrates safety and prolonged duration of effect in a dose-ranging study for glabellar lines
Product Name : Xeomin
Product Type : Protein
Upfront Cash : Inapplicable
March 31, 2022
Lead Product(s) : Incobotulinumtoxin A
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Incobotulinumtoxin A
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The approval by European authorities for the use of XEOMIN® for pediatric patients suffering from chronic sialorrhea, was achieved due to the convincing results of the SIPEXI study (Sialorrhea Pediatric Xeomin Investigation).
Product Name : Xeomin
Product Type : Protein
Upfront Cash : Inapplicable
August 31, 2021
Lead Product(s) : Incobotulinumtoxin A
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : L-Ornithine L-aspartate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Hong Kong Winhealth Pharma Group
Deal Size : Undisclosed
Deal Type : Collaboration
Winhealth Pharma and Merz Collaborate on Hepa-Merz® to benefit patients with liver disease in China
Details : The strategic cooperation between the two parties marks the obtainment of Winhealth Pharma for the exclusive commercial rights of Hepa-Merz® (L-ornithine L-aspartate, an important product under Merz' product portfolio) in China.
Product Name : Hepa-Merz
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 03, 2021
Lead Product(s) : L-Ornithine L-aspartate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Hong Kong Winhealth Pharma Group
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Incobotulinumtoxin A
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Health Canada Licenses XEOMIN® (incobotulinumtoxinA) for Adult Patients With Sialorrhea
Details : XEOMIN was licensed by Health Canada for adult patients with sialorrhea on the basis of a Phase III, randomized, double-blind, placebo-controlled, multicenter trial in which 184 patients participated.
Product Name : Xeomin
Product Type : Protein
Upfront Cash : Inapplicable
January 12, 2020
Lead Product(s) : Incobotulinumtoxin A
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
